Cancer-fighting biotech takes step closer to being Bay Area’s third IPO of the year

The South San Francisco cancer-focused biotech hopes to raise up to $92 million in an offering that would value the business as high as about $368 million.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.